ST5 Antibody (C-term) Blocking Peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P78524 |
---|---|
Other Accession | NP_005409 |
Clone Names | 2090901 |
Gene ID | 6764 |
---|---|
Other Names | Suppression of tumorigenicity 5 protein, DENN domain-containing protein 2B, HeLa tumor suppression 1, ST5, DENND2B, HTS1 |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6249a was selected from the C-term region of human ST5 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | DENND2B (HGNC:11350) |
---|---|
Function | [Isoform 1]: May be involved in cytoskeletal organization and tumorogenicity. Seems to be involved in a signaling transduction pathway leading to activation of MAPK1/ERK2. Plays a role in EGFR trafficking from recycling endosomes back to the cell membrane (PubMed:29030480). |
Cellular Location | [Isoform 1]: Cytoplasm, cell cortex. Cell membrane. Recycling endosome. Note=Colocalizes with RAB13 and ITSN1 at cytoplasmic vesicles that are most likely recycling endosomes Colocalizes with the cortical actin cytoskeleton |
Tissue Location | Widely expressed with the exception of peripheral blood lymphocytes. Isoform 1 is expressed in several epithelial and fibroblast (including tumorigenic) but absent in lymphoid cell lines (at protein level). Isoform 3 is expressed in primary cell or weakly tumorigenic but not in tumorigenic cell lines (at protein level) |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
ST5 was identified by its ability to suppress the tumorigenicity of Hela cells in nude mice. The protein contains a C-terminal region that shares similarity with the Rab 3 family of small GTP binding proteins. This protein preferentially binds to the SH3 domain of c-Abl kinase, and acts as a regulator of MAPK1/ERK2 kinase, which may contribute to its ability to reduce the tumorigenic phenotype in cells.
References
Majidi, M., et al., J. Biol. Chem. 275(9):6560-6565 (2000).Hubbs, A.E., et al., Oncogene 18(15):2519-2525 (1999).Majidi, M., et al., J. Biol. Chem. 273(26):16608-16614 (1998).Lichy, J.H., et al., Nucleic Acids Res. 24(23):4700-4708 (1996).Lichy, J.H., et al., Cell Growth Differ. 3(8):541-548 (1992).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.